<DOC>
	<DOCNO>NCT01277991</DOCNO>
	<brief_summary>In study , 5 mg dose CP-690,550 give study subject two separate occasion use one two different strength tablet time . The amount CP-690,550 available blood follow administration tablet measure compare . The overall aim study establish similar amount CP-690,550 absorb blood follow administration dose different strength tablet .</brief_summary>
	<brief_title>A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550</brief_title>
	<detailed_description>This bioequivalence study CP-690,550 .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<criteria>Healthy male and/or female ( nonchildbearing potential ) subject age 21 55 year , inclusive . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . No evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) . Subjects evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Personal family history hereditary immunodeficiency ( eg , severe Evidence clinically significant illness , medical condition , disease . Evidence history clinically significant infection within past 3 month . Use tobacco nicotinecontaining product excess equivalent 5 cigarette per day .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>healthy volunteer study</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>